tetano
Editor, Senior Moderator
J Med Virol
. 2023 Nov;95(11):e29231.
doi: 10.1002/jmv.29231. Investigating the impact of Sinopharm COVID-19 vaccination on antibody response in pregnant women and their newborns
Tahoora Abdolahi[SUP] 1 [/SUP], Gholamali Maamouri[SUP] 2 [/SUP], Maryam Behmadi[SUP] 2 [/SUP], Sara Mirzaeian[SUP] 3 [/SUP], Hassan Boskabadi[SUP] 2 [/SUP], Raheleh Faramarzi[SUP] 2 [/SUP]
Affiliations
This study aims to investigate the levels of receptor-binding domain (RBD), spike, and neutralizing antibodies in pregnant women who received the Sinopharm vaccine and their newborns. A cross-sectional study was conducted at a tertiary center, Mashhad, Iran. We included 88 pregnant women who had received at least two doses of the Sinopharm vaccine. Maternal and umbilical cord blood samples taken at delivery were analyzed for antibodies using ELISA tests. Antibody levels did not vary significantly between women with two or three vaccine doses. Only 1.1% of mothers had undetectable levels of RBD antibodies, but detectable antibodies were observed in all newborns. A significant linear correlation was found between the levels of neutralizing antibodies (r = 0.7, p < 0.001) and RBD antibodies (r = 0.833, p < 0.001) in mothers and their newborns, but not for Spike antibodies (r = 0.214, p = 0.045). In mothers, high titers of antispike and RBD antibodies were observed at the time of delivery. The high titers of RBD and antispike antibodies were found in cord blood, suggesting potential neonatal immunity. Detectable levels of antibodies were found in both groups, regardless of the timing of vaccination. The Sinopharm vaccine generates detectable levels of antibodies in pregnant women, which are efficiently transferred to their newborns. The number of vaccine doses (two or three) did not significantly impact the levels of detectable antibodies. This underscores Sinopharm's potential efficacy in protecting pregnant women and their infants from COVID-19.
Keywords: coronavirus; immune response; vertical transmission.
. 2023 Nov;95(11):e29231.
doi: 10.1002/jmv.29231. Investigating the impact of Sinopharm COVID-19 vaccination on antibody response in pregnant women and their newborns
Tahoora Abdolahi[SUP] 1 [/SUP], Gholamali Maamouri[SUP] 2 [/SUP], Maryam Behmadi[SUP] 2 [/SUP], Sara Mirzaeian[SUP] 3 [/SUP], Hassan Boskabadi[SUP] 2 [/SUP], Raheleh Faramarzi[SUP] 2 [/SUP]
Affiliations
- PMID: 37971780
- DOI: 10.1002/jmv.29231
This study aims to investigate the levels of receptor-binding domain (RBD), spike, and neutralizing antibodies in pregnant women who received the Sinopharm vaccine and their newborns. A cross-sectional study was conducted at a tertiary center, Mashhad, Iran. We included 88 pregnant women who had received at least two doses of the Sinopharm vaccine. Maternal and umbilical cord blood samples taken at delivery were analyzed for antibodies using ELISA tests. Antibody levels did not vary significantly between women with two or three vaccine doses. Only 1.1% of mothers had undetectable levels of RBD antibodies, but detectable antibodies were observed in all newborns. A significant linear correlation was found between the levels of neutralizing antibodies (r = 0.7, p < 0.001) and RBD antibodies (r = 0.833, p < 0.001) in mothers and their newborns, but not for Spike antibodies (r = 0.214, p = 0.045). In mothers, high titers of antispike and RBD antibodies were observed at the time of delivery. The high titers of RBD and antispike antibodies were found in cord blood, suggesting potential neonatal immunity. Detectable levels of antibodies were found in both groups, regardless of the timing of vaccination. The Sinopharm vaccine generates detectable levels of antibodies in pregnant women, which are efficiently transferred to their newborns. The number of vaccine doses (two or three) did not significantly impact the levels of detectable antibodies. This underscores Sinopharm's potential efficacy in protecting pregnant women and their infants from COVID-19.
Keywords: coronavirus; immune response; vertical transmission.